We surmise that the application of high-content, high-throughput technologies to heterotypic experimental settings that involve not only malignant cells but also various other components of the tumor microenvironment (including endothelial, mesenchymal and immune cells) is the key for the development of efficient strategies to restore the sensitivity of multiple human neoplasms to CDDP.
(2) Tumor Microenvironment.
Our integrin specific ligand functionalized 3D organoids mimic a lymphoid neoplasm-like heterogeneous microenvironment that could, in the long term, change the understanding of the initiation and progression of hematological tumors, allow primary biospecimen analysis, provide prognostic values, and importantly, allow a faster and more rational screening and translation of therapeutic regimens.
Furthermore previous studies have demonstrated the presence of PD1 expression on infiltrating T-cell populations and PD-L1 CD274 PD-L1 CD274cells and in the micronnvironmentumourLBcellsd relandd neoplasms [ 50, 51].
Metastasis to bone is a complex multistep event, which involves a bidirectional interaction of the tumor cells with cellular elements in three different micro-environments [ 7]: the site of primary neoplasm, the circulation, and the bone microenvironment.
The microenvironment of the tumor highly resembles an inflammation site which results from enhancement of the levels of cytokines, chemokines, neutrophils, eosinophils, mast cells, lymphocytes, and macrophages both in the surrounding stroma and within the neoplasm itself [ 3].
However, involvement of the Hh-signaling system in the bone marrow (BM) microenvironment during the development of myeloid neoplasms is unknown.
The neoplastic cells are offspring of HPCs and each can differentiate a little differently, according to the local microenvironment in each part of the tumor if it explains the enormous phenotypic heterogeneity of a neoplasm [ 4].
The interaction of the cancer cells with their microenvironment is one of these fundamental features of neoplasms that could be targeted in such cancer treatments.
